Lynda Spelman

6.1k total citations · 1 hit paper
89 papers, 3.2k citations indexed

About

Lynda Spelman is a scholar working on Dermatology, Immunology and Epidemiology. According to data from OpenAlex, Lynda Spelman has authored 89 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Dermatology, 30 papers in Immunology and 29 papers in Epidemiology. Recurrent topics in Lynda Spelman's work include Psoriasis: Treatment and Pathogenesis (29 papers), Nonmelanoma Skin Cancer Studies (25 papers) and Dermatology and Skin Diseases (22 papers). Lynda Spelman is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (29 papers), Nonmelanoma Skin Cancer Studies (25 papers) and Dermatology and Skin Diseases (22 papers). Lynda Spelman collaborates with scholars based in Australia, United States and Canada. Lynda Spelman's co-authors include Kim Papp, Mark Lebwohl, Kristian Reich, Enrique Rivas, Richard G. Langley, C.E.M. Griffiths, C. Papavassilis, Bárður Sigurgeirsson, Dédée F. Murrell and Thomas Salko and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lynda Spelman

79 papers receiving 3.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

2014 1.5k citations Mark Lebwohl, Kim Papp et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Lynda Spelman	1.7k	1.6k	951	467	453	89	3.2k
M. Viguier	729 0.4×	1.6k 1.0×	389 0.4×	159 0.3×	489 1.1×	125	3.0k
Edward W. Cowen	602 0.3×	852 0.5×	587 0.6×	426 0.9×	389 0.9×	155	3.2k
Vincent Ho	1.2k 0.7×	1.4k 0.9×	577 0.6×	98 0.2×	332 0.7×	63	2.8k
V. Descamps	672 0.4×	646 0.4×	593 0.6×	153 0.3×	1.0k 2.3×	165	3.0k
José M. Mascaró	1.1k 0.7×	606 0.4×	680 0.7×	275 0.6×	1.4k 3.1×	273	4.3k
Sarolta Kárpáti	575 0.3×	730 0.4×	692 0.7×	238 0.5×	1.1k 2.5×	199	4.2k
M. Beylot‐Barry	3.2k 1.8×	1.4k 0.8×	1.7k 1.8×	241 0.5×	679 1.5×	337	5.7k
Elena Netchiporouk	972 0.6×	441 0.3×	416 0.4×	151 0.3×	369 0.8×	116	2.0k
Peter Von Den Driesch	1.0k 0.6×	1.6k 1.0×	1.2k 1.3×	105 0.2×	206 0.5×	82	3.6k
Ketty Peris	1.3k 0.8×	376 0.2×	704 0.7×	157 0.3×	245 0.5×	169	2.2k

Countries citing papers authored by Lynda Spelman

Since Specialization

Citations

This map shows the geographic impact of Lynda Spelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynda Spelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynda Spelman more than expected).

Fields of papers citing papers by Lynda Spelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynda Spelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynda Spelman. The network helps show where Lynda Spelman may publish in the future.

Co-authorship network of co-authors of Lynda Spelman

This figure shows the co-authorship network connecting the top 25 collaborators of Lynda Spelman. A scholar is included among the top collaborators of Lynda Spelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynda Spelman. Lynda Spelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guttman‐Yassky, Emma, Eric L. Simpson, Robert Bissonnette, et al.. (2025). ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 17(2). 83–94. 5 indexed citations

Guttman‐Yassky, Emma, Alan D. Irvine, Eric L. Simpson, et al.. (2025). Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin. SKIN The Journal of Cutaneous Medicine. 9(1). s510–s510.

Gebauer, Kurt, Lynda Spelman, Paul S. Yamauchi, et al.. (2024). Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. Journal of the American Academy of Dermatology. 91(1). 91–99. 6 indexed citations

Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2024). Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. British Journal of Dermatology. 190(5). 668–679. 35 indexed citations

Korman, Neil J., Thierry Passeron, Yukari Okubo, et al.. (2024). Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8(6). s419–s419. 2 indexed citations

Sofen, Howard, Kurt Gebauer, Lynda Spelman, et al.. (2024). Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 92(4). 816–824.

Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2024). Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology. 161(1). 56–56. 11 indexed citations

Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2024). Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8(4). s406–s406. 2 indexed citations

Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2024). Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8(6). s423–s423. 1 indexed citations

10.

Wang, Junying, et al.. (2023). Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clinical and Translational Science. 16(12). 2614–2627. 13 indexed citations

11.

Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2023). Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 7(2). s118–s118. 3 indexed citations

12.

Lee, Ruby, Susan D. Brown, Lynda Spelman, et al.. (2023). Patterns and cost of care according to keratinocyte cancer risk stratification in a volunteer population screening clinic: Real‐world data from the TRoPICS study. Australasian Journal of Dermatology. 64(3). 389–396. 1 indexed citations

13.

Guttman‐Yassky, Emma, Stephan Weidinger, Eric L. Simpson, et al.. (2023). Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7(6). s271–s271. 1 indexed citations

14.

Yamada, Miko, Dennis M. Miller, Melinda Lowe, et al.. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications. 23. 100830–100830. 25 indexed citations

15.

Goodman, Greg, et al.. (2021). Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat. Dermatologic Surgery. 47(8). 1065–1070. 5 indexed citations

16.

Calao, Miriam, et al.. (2018). Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLoS ONE. 13(7). e0200683–e0200683. 75 indexed citations

17.

Smith, Peter, Mimi L.K. Tang, Lynda Spelman, et al.. (2017). Debunking the Myth of Wool Allergy: Reviewing the Evidence for Immune and Non-immune Cutaneous Reactions. Acta Dermato Venereologica. 97(8). 906–915. 17 indexed citations

18.

Rowe, Casey, et al.. (2013). Isotretinoin and mental health in adolescents: Australian consensus. Australasian Journal of Dermatology. 55(2). 162–167. 11 indexed citations

19.

De’Ambrosis, Brian, et al.. (2006). Seborrhoeic keratosis and malignancy: Collision tumour or malignant transformation?. Australasian Journal of Dermatology. 47(2). 106–108. 31 indexed citations

20.

Vinciullo, Carl, David M. Francis, Kurt Gebauer, et al.. (2005). Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. British Journal of Dermatology. 152(4). 765–772. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact